These findings suggest that the synergistic effect of GM-CSF and IL-21 significantly enhances systemic anti-tumor activity and that the VVL therapeutic platform can broaden the scope of ICI and cancer vaccine treatments. The gene discussed is CSF2; the disease is neoplasm.